Biotech Values

[Whalatane]

ICU and UNCY update ..part deux .
ICU ..turns out the recent funding was all institutional. Institutions now hold close to 22% of the outstanding shares vs 5% previously
Funding to aggressively complete enrollment of their pivotal trial ..just my WAG ( wild ass guess )

UNCY ..ARDX just released their earnings report .
They declared revenue of $25 m for the qt for their sales of Xphozah ..used to lower serum phosphorus in dialysis patient ...DESPITE no Medicare coverage .
90% of dialysis patients are on Medicare ...so 90% of those on dialysis have no reimbursement for Xphozah ...yet they sell $25m of it last Qt .

That tells me dialysis patients hate their current pho binders .
UNCY has a pho binder thats awaiting approval and will be 100% reimbursed by Medicare for the first 2 yrs in TDAPA with declining coverage after that .
The problem is that a cGMP manufacturing issue has delayed approval ...and that may delay approval to mid 2026 .
But once approved ..if the sales of Xphozah is any indication ...50% complain of diarrhea on Xphozah ...UNCY's OLC could be a game changer
JMO and WAG
Kiwi